Wiggins visited Dr. Andrea Sant’s lab to deepen her understanding of CD4+ T-cell responses to a COBRA-designed influenza vaccine candidate administered to obese mouse models.
André León discusses his experience studying influenza coast to coast. Follow his journey to New York City for virology training in the Krammer lab!
CIVR-HRP researchers found that live attenuated versus inactivated influenza vaccines differ in the quality and quantity of immune responses.
Dr. Kevin McCarthy discusses his experience completing a project through the Fall 2023 cycle of the CIVICs Collaborative Training Program.
The CIVICs Network is thrilled to congratulate Dr. Drew Weissman, an investigator who is part of the Duke CIVIC Vaccine Center, on winning the 2023
Coronaviruses and influenza viruses pose a major risk to global health, underscored by the impact of the COVID-19 pandemic and continuing spread of SARS-CoV-2 variants.
The Duke CIVIC Vaccine Center (DCVC) hosted a hybrid annual retreat on May 4 and 5, the second retreat since the contract’s inception in September
The National Institute of Allergy and Infectious Diseases (NIAID) announced that the Duke Human Vaccine Institute (DHVI) has initiated enrollment of volunteers for a clinical
Florian Krammer, Principal Investigator of SEM-CIVIC, was elected to the 2023 Fellowship Class for the American Academy of Microbiology for his significant contributions to the field of microbiology.
The Pharmaceutical Society of Japan awarded Dr. Kristy Ainslie, of CIVR-HRP, the 2023 Sato Memorial International Award for her notable achievements in the field of pharmaceutical sciences.